RUA has reported its second interim results covering the 12-months to March 2025, which reflect the trading update provided in April 2025. For the period, the company reported revenues of £4.1m, gross profit of £3.1m and an operating loss of £20k, benefiting from a c£1m gain on the acquisition of ABISS. The company closed the period with cash of £3.6m. These results are in-line with the trading update and marginally ahead of our forecasts for the period, though we note our ‘in-market’ forecasts ....

25 Jun 2025
RUA Life Sciences - Interim results – Substantial progress made

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
RUA Life Sciences - Interim results – Substantial progress made
RUA Life Sciences Plc (RUA:LON) | 12.6 0 0.0% | Mkt Cap: 7.84m
- Published:
25 Jun 2025 -
Author:
Chris Donnellan -
Pages:
7 -
RUA has reported its second interim results covering the 12-months to March 2025, which reflect the trading update provided in April 2025. For the period, the company reported revenues of £4.1m, gross profit of £3.1m and an operating loss of £20k, benefiting from a c£1m gain on the acquisition of ABISS. The company closed the period with cash of £3.6m. These results are in-line with the trading update and marginally ahead of our forecasts for the period, though we note our ‘in-market’ forecasts ....